본문 바로가기
KERD
논문KCI 등재

인크레틴 기반 비만 치료제의 최근 발전 상황

Recent Progression of Incretin-Based Obesity Treatment

최덕현
대한내과학회 (The Korean Association Of Internal Medicine)|2024.04|대한내과학회지 (The Korean Journal of Medicine)|제99권 제2호|pp. 78-83|DOI https://doi.org/10.3904/kjm.2024.99.2.78

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

비만ObesityIncretinsGlucagon-like peptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptide인크레틴글루카곤유사펩타이드-1수용체작용제포도당의존인슐린자극폴리펩타이드
주제분류내과학

초록

Incretin-based obesity treatments are making remarkable progress, marking a new era in the field of obesity pharmacotherapy. These treatments not only meet the long-standing demands for safety and sustainability in obesity medications but also go beyond, significantly improving complications associated with obesity, such as cardiovascular diseases. This review explores the advancement in obesity treatments through the latest research findings on semaglutide and tirzepatide, two incretin-based obesity treatments currently receiving considerable attention.

Abstract

Incretin-based obesity treatments are making remarkable progress, marking a new era in the field of obesity pharmacotherapy. These treatments not only meet the long-standing demands for safety and sustainability in obesity medications but also go beyond, significantly improving complications associated with obesity, such as cardiovascular diseases. This review explores the advancement in obesity treatments through the latest research findings on semaglutide and tirzepatide, two incretin-based obesity treatments currently receiving considerable attention.

참고문헌 (26)

  1. Evans M, "Obesity-related complications, healthcare resource use and weight loss strategies in six European countries : the RESOURCE survey", Int J Obes(Lond), 47, pp.750~757 (2023)
  2. Li MF, "Rise and fall of anti-obesity drugs", World J Diabetes, 2, pp.19~23 (2011)
  3. Tak YJ, "Anti-obesity drugs : long-term efficacy and safety : an updated review", World J Mens Health, 39, pp.208~221 (2021)
  4. Connolly HM, "Valvular heart disease associated with fenfluramine-phentermine", N Engl J Med, 337, pp.581~588 (1997)
  5. Kernan WN, "Phenylpropanolamine and the risk of hemorrhagic stroke", N Engl J Med, 343, pp.1826~1832 (2000)
  6. James WP, "Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects", N Engl J Med, 363, pp.905~917 (2010)
  7. Jeong IK, "Extrapancreatic effect of glucagon like peptide-1", Korean J Med, 89, pp.404~412 (2015)
  8. Tan Q, "Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes", Front Endocrinol(Lausanne), 13, pp.838410~ (2022)
  9. Jung HN, "The upcoming weekly tides(semaglutide vs. tirzepatide)against obesity : STEP or SURPASS?", J Obes Metab Syndr, 31, pp.28~36 (2022)
  10. Wilding JPH, "Once-weekly semaglutide in adults with overweight or obesity", N Engl J Med, 384, pp.989~1002 (2021)
  11. Davies M, "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2diabetes(STEP 2) : a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial", Lancet, 397, pp.971~984 (2021)
  12. Wadden TA, "Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity : the STEP 3 randomized clinical trial", JAMA, 325, pp.1403~1413 (2021)
  13. Rubino D, "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity : the STEP 4 randomized clinical trial", JAMA, 325, pp.1414~1425 (2021)
  14. Garvey WT, "Two-year effects of semaglutide in adults with overweight or obesity : the STEP 5 trial", Nat Med, 28, pp.2083~2091 (2022)
  15. Rubino DM, "Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes : the STEP 8 randomized clinical trial", JAMA, 327, pp.138~150 (2022)
  16. Kadowaki T, "Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population(STEP 6) : a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial", Lancet Diabetes Endocrinol, 10, pp.193~206 (2022)
  17. Mu Y, "Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity(STEP 7) : a double-blind, multicentre, randomised controlled trial", Lancet Diabetes Endocrinol, 12, pp.184~195 (2024)
  18. Kosiborod MN, "Semaglutide in patients with heart failure with preserved ejection fraction and obesity", N Engl J Med, 389, pp.1069~1084 (2023)
  19. Lincoff AM, "Semaglutide and cardiovascular outcomes in obesity without diabetes", N Engl J Med, 389, pp.2221~2232 (2023)
  20. Jastreboff AM, "Tirzepatide once weekly for the treatment of obesity", N Engl J Med, 387, pp.205~216 (2022)
  21. Garvey WT, "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes(SURMOUNT-2) : a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 402, pp.613~626 (2023)
  22. Wadden TA, "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity : the SURMOUNT-3 phase 3 trial", Nat Med, 29, pp.2909~2918 (2023)
  23. Aronne LJ, "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity : the SURMOUNT-4 randomized clinical trial", JAMA, 331, pp.38~48 (2024)
  24. Sinha R, "Efficacy and safety of tirzepatide in type 2 diabetes and obesity management", J Obes Metab Syndr, 32, pp.25~45 (2023)
  25. Alicic RZ, "Incretin therapies for patients with type 2 diabetes and chronic kidney disease", J Clin Med, 13, pp.201~ (2023)
  26. Jastreboff AM, "Triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial", N Engl J Med, 389, pp.514~526 (2023)

관련 논문AI추천

비만 치료에서 semaglutide의 효능 및 안전성에 대한 고찰박태은, 한승훈한국임상약학회 · 한국임상약학회지2024 · 제34권 제1호Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes이동윤, 이승아대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제1호비만 치료의 최신 지견김민정, 안상준, 이철진대한임상건강증진학회 · Korean Journal of Health Promotion2019 · 제19권 제4호The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist조윤경, Chang Hee Jung, Yoo La Lee한국지질동맥경화학회 · 지질·동맥경화학회지2023 · 제12권 제3호제 2형 당뇨병 치료제의 개발 동향김익환, 이수현, 이종근한국미생물·생명공학회 · 한국미생물·생명공학회지2012 · 제40권 제3호제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법김헌성, 김현아한국임상약학회 · 한국임상약학회지2011 · 제21권 제2호

이 간행물의 다른 논문 (9건)

급성 흉통 환자에 대한 권역 내 이송 체계 구축배장환pp. 57-60SGLT2 억제제와 만성 콩팥병배은희, 송수현pp. 61-68과민성폐렴의 진단, 임상 경과 및 치료박종선pp. 69-77Human Understanding is Expected of the Physician: Proposing a Model of Disease Development장성혜, 장시형, 문종호, 박삼엘, 전성완, 배상병, 박상흠, 이상미, 김진영, 이현아, 이태훈pp. 84-95비소세포폐암 환자의 표적 치료함수연, 강두영, 남희림, 이윤규, 길현일, 이현주, 김수정pp. 96-103
원문 보기